Fractyl Health initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Fractyl Health (GUTS) with a Buy rating and $9 price target Fractyl is a clinical stage biotechnology company focused on developing one-time, long-lasting, disease-modifying treatments for obesity and type 2 diabetes, targeting the gut and the pancreas as the root-cause organs of metabolic diseases, the analyst tells investors in a research note. The firm says Fractyl’s Revita and Rejuva have exhibited sustained weight loss and glucose control efficacy, with favorable safety and tolerability profiles.